2011, ISBN 9781439816868, xxii, 577
Book
2011, 1., ISBN 9780309211093, xviii, 542 p. ; 23 cm.
Book
JAMA, ISSN 0098-7484, 06/2014, Volume 311, Issue 23, pp. 2387 - 2396
IMPORTANCE In older adults reduced mobility is common and is an independent risk factor for morbidity, hospitalization, disability, and mortality. Limited...
MORTALITY | MEDICINE, GENERAL & INTERNAL | INDEPENDENCE | ELDERS | PERFORMANCE | PREDICTORS | SUBSEQUENT DISABILITY | LOWER-EXTREMITY FUNCTION | KNEE OSTEOARTHRITIS | GAIT SPEED | STYLE INTERVENTIONS | Single-Blind Method | Life Style | Humans | Male | Risk | Sedentary Lifestyle | Exercise Therapy | Walking | Exercise | Aged, 80 and over | Female | Aged | Motor Skills Disorders - prevention & control | Disabled Persons | Health Education | Exercise for the aged | Research | Health aspects | Disease prevention | Physical fitness | Risk assessment | Older people | Motor ability | Clinical outcomes
MORTALITY | MEDICINE, GENERAL & INTERNAL | INDEPENDENCE | ELDERS | PERFORMANCE | PREDICTORS | SUBSEQUENT DISABILITY | LOWER-EXTREMITY FUNCTION | KNEE OSTEOARTHRITIS | GAIT SPEED | STYLE INTERVENTIONS | Single-Blind Method | Life Style | Humans | Male | Risk | Sedentary Lifestyle | Exercise Therapy | Walking | Exercise | Aged, 80 and over | Female | Aged | Motor Skills Disorders - prevention & control | Disabled Persons | Health Education | Exercise for the aged | Research | Health aspects | Disease prevention | Physical fitness | Risk assessment | Older people | Motor ability | Clinical outcomes
Journal Article
Climacteric, ISSN 1369-7137, 10/2014, Volume 17, Issue 5, pp. 540 - 556
Abstract Women may expect to spend more than a third of their lives after menopause. Beginning in the sixth decade, many chronic diseases will begin to emerge,...
OBESITY | HORMONAL THERAPY | CARDIOVASCULAR | DEMENTIA | PREVENTION | MENOPAUSE | COGNITION | CANCER | OSTEOPOROSIS | hormonal therapy | cognition | menopause | dementia | cancer | cardiovascular | osteoporosis | obesity | prevention | BREAST-CANCER INCIDENCE | RANDOMIZED CONTROLLED-TRIAL | HORMONE REPLACEMENT THERAPY | CONJUGATED EQUINE ESTROGEN | OBSTETRICS & GYNECOLOGY | OSTEOPOROSIS-RELATED FRACTURES | BODY-MASS INDEX | CORONARY-HEART-DISEASE | ESTROGEN PLUS PROGESTIN | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK-FACTORS | Osteoporosis, Postmenopausal - epidemiology | Neoplasms - etiology | Women's Health | Cardiovascular Diseases - prevention & control | Humans | Menopause | Middle Aged | Neoplasms - prevention & control | Dementia - epidemiology | Chronic Disease - prevention & control | Osteoarthritis - epidemiology | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Postmenopause | Female | Obesity - etiology | Osteoporosis, Postmenopausal - prevention & control | Osteoporosis, Postmenopausal - etiology | Cardiovascular Diseases - etiology | Risk Reduction Behavior | Osteoarthritis - prevention & control | Risk Factors | Chronic Disease - epidemiology | Estrogen Replacement Therapy - adverse effects | Dementia - etiology | Obesity - epidemiology | Obesity - prevention & control | Quality of Life | Aged | Dementia - prevention & control | Early Diagnosis | Osteoarthritis - etiology | Neoplasms - epidemiology
OBESITY | HORMONAL THERAPY | CARDIOVASCULAR | DEMENTIA | PREVENTION | MENOPAUSE | COGNITION | CANCER | OSTEOPOROSIS | hormonal therapy | cognition | menopause | dementia | cancer | cardiovascular | osteoporosis | obesity | prevention | BREAST-CANCER INCIDENCE | RANDOMIZED CONTROLLED-TRIAL | HORMONE REPLACEMENT THERAPY | CONJUGATED EQUINE ESTROGEN | OBSTETRICS & GYNECOLOGY | OSTEOPOROSIS-RELATED FRACTURES | BODY-MASS INDEX | CORONARY-HEART-DISEASE | ESTROGEN PLUS PROGESTIN | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK-FACTORS | Osteoporosis, Postmenopausal - epidemiology | Neoplasms - etiology | Women's Health | Cardiovascular Diseases - prevention & control | Humans | Menopause | Middle Aged | Neoplasms - prevention & control | Dementia - epidemiology | Chronic Disease - prevention & control | Osteoarthritis - epidemiology | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Postmenopause | Female | Obesity - etiology | Osteoporosis, Postmenopausal - prevention & control | Osteoporosis, Postmenopausal - etiology | Cardiovascular Diseases - etiology | Risk Reduction Behavior | Osteoarthritis - prevention & control | Risk Factors | Chronic Disease - epidemiology | Estrogen Replacement Therapy - adverse effects | Dementia - etiology | Obesity - epidemiology | Obesity - prevention & control | Quality of Life | Aged | Dementia - prevention & control | Early Diagnosis | Osteoarthritis - etiology | Neoplasms - epidemiology
Journal Article
The Journal of Bone and Joint Surgery, ISSN 0021-9355, 08/2014, Volume 96, Issue 15, pp. e130 - e130
Osteoarthritis is a leading cause of disability. The traditional focus on late-stage osteoarthritis has not yielded effective disease-modifying treatments....
SURGERY | CHONDROCYTE DEATH | ARTICULAR-CARTILAGE | POSTTRAUMATIC OSTEOARTHRITIS | FEMOROACETABULAR IMPINGEMENT | BERNESE PERIACETABULAR OSTEOTOMY | FOLLOW-UP | ANTERIOR CRUCIATE LIGAMENT | ORTHOPEDICS | IMPACT INJURY | HIP | DEGENERATION | Osteoarthritis - surgery | Osteoarthritis - prevention & control | Humans | Risk Factors | Osteoarthritis - diagnostic imaging | Palliative Care | Osteoarthritis - therapy | Animals | Orthopedic Procedures | Intra-Articular Fractures - etiology | Mice | Early Diagnosis | Anterior Cruciate Ligament Injuries - etiology | Disease Models, Animal | Osteoarthritis - complications | 0090 | 0010 | The Orthopaedic Forum | 0070
SURGERY | CHONDROCYTE DEATH | ARTICULAR-CARTILAGE | POSTTRAUMATIC OSTEOARTHRITIS | FEMOROACETABULAR IMPINGEMENT | BERNESE PERIACETABULAR OSTEOTOMY | FOLLOW-UP | ANTERIOR CRUCIATE LIGAMENT | ORTHOPEDICS | IMPACT INJURY | HIP | DEGENERATION | Osteoarthritis - surgery | Osteoarthritis - prevention & control | Humans | Risk Factors | Osteoarthritis - diagnostic imaging | Palliative Care | Osteoarthritis - therapy | Animals | Orthopedic Procedures | Intra-Articular Fractures - etiology | Mice | Early Diagnosis | Anterior Cruciate Ligament Injuries - etiology | Disease Models, Animal | Osteoarthritis - complications | 0090 | 0010 | The Orthopaedic Forum | 0070
Journal Article
CIRCULATION, ISSN 0009-7322, 03/2009, Volume 119, Issue 11, pp. 1541 - 1551
Primary prevention of acute rheumatic fever is accomplished by proper identification and adequate antibiotic treatment of group A beta-hemolytic streptococcal...
UNITED-STATES | CEFUROXIME AXETIL | UPPER RESPIRATORY-TRACT | CARDIAC & CARDIOVASCULAR SYSTEMS | POSTSTREPTOCOCCAL REACTIVE ARTHRITIS | infectious diseases | ANTIBIOTIC-RESISTANCE | rheumatic fever | AHA Scientific Statements | GROUP-A STREPTOCOCCI | rheumatic heart disease | pediatrics | TWICE-DAILY PENICILLIN | OBSESSIVE-COMPULSIVE SYMPTOMS | STREPTOZYME TEST | PERIPHERAL VASCULAR DISEASE | streptococcal pharyngitis | DAILY AMOXICILLIN | prevention | American Heart Association | Pharyngitis - microbiology | Anti-Bacterial Agents - therapeutic use | Acute Disease | United States | Humans | Rheumatic Heart Disease - drug therapy | Pharyngitis - drug therapy | Rheumatic Heart Disease - prevention & control | Secondary Prevention | Rheumatic Heart Disease - diagnosis | Prevention | Care and treatment | Pharyngitis | Rheumatic fever
UNITED-STATES | CEFUROXIME AXETIL | UPPER RESPIRATORY-TRACT | CARDIAC & CARDIOVASCULAR SYSTEMS | POSTSTREPTOCOCCAL REACTIVE ARTHRITIS | infectious diseases | ANTIBIOTIC-RESISTANCE | rheumatic fever | AHA Scientific Statements | GROUP-A STREPTOCOCCI | rheumatic heart disease | pediatrics | TWICE-DAILY PENICILLIN | OBSESSIVE-COMPULSIVE SYMPTOMS | STREPTOZYME TEST | PERIPHERAL VASCULAR DISEASE | streptococcal pharyngitis | DAILY AMOXICILLIN | prevention | American Heart Association | Pharyngitis - microbiology | Anti-Bacterial Agents - therapeutic use | Acute Disease | United States | Humans | Rheumatic Heart Disease - drug therapy | Pharyngitis - drug therapy | Rheumatic Heart Disease - prevention & control | Secondary Prevention | Rheumatic Heart Disease - diagnosis | Prevention | Care and treatment | Pharyngitis | Rheumatic fever
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2019, Volume 380, Issue 8, pp. 752 - 762
Patients with coronary artery disease were randomly assigned to either methotrexate (15 to 20 mg weekly) or placebo. At a median of 2.3 years, there was no...
C-REACTIVE PROTEIN | RHEUMATOID-ARTHRITIS | TRIAL | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | REDUCTION | CANTOS | INFLAMMATION | DISEASE | RISK | CANCER | Confidence Intervals | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Interleukin-1beta - blood | Interleukin-6 - blood | Statistics, Nonparametric | Cardiovascular Diseases - mortality | Female | C-Reactive Protein - analysis | Diabetes Mellitus, Type 2 - complications | Immunosuppressive Agents - administration & dosage | Stroke - prevention & control | Double-Blind Method | Proportional Hazards Models | Coronary Artery Disease - drug therapy | Metabolic Syndrome - complications | Methotrexate - adverse effects | Myocardial Infarction - complications | Stroke - etiology | Myocardial Infarction - drug therapy | Coronary Artery Disease - complications | Immunosuppressive Agents - adverse effects | Methotrexate - administration & dosage | Transaminases - blood | Aged | Atherosclerosis - prevention & control | Myocardial infarction | C-reactive protein | Heart attacks | Liver | Hematocrit | Cardiovascular disease | Angina | Metabolic syndrome | Folic acid | Interleukin 6 | Proteins | Atherosclerosis | Methotrexate | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Cerebral infarction | Cytokines | Diabetes mellitus | Inflammation | IL-1β | Patients | Investigations | Disease prevention | Rheumatoid arthritis | Arteriosclerosis | Monoclonal antibodies | Diabetes | Health risk assessment | Metabolic disorders | Pharmaceuticals
C-REACTIVE PROTEIN | RHEUMATOID-ARTHRITIS | TRIAL | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | REDUCTION | CANTOS | INFLAMMATION | DISEASE | RISK | CANCER | Confidence Intervals | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Interleukin-1beta - blood | Interleukin-6 - blood | Statistics, Nonparametric | Cardiovascular Diseases - mortality | Female | C-Reactive Protein - analysis | Diabetes Mellitus, Type 2 - complications | Immunosuppressive Agents - administration & dosage | Stroke - prevention & control | Double-Blind Method | Proportional Hazards Models | Coronary Artery Disease - drug therapy | Metabolic Syndrome - complications | Methotrexate - adverse effects | Myocardial Infarction - complications | Stroke - etiology | Myocardial Infarction - drug therapy | Coronary Artery Disease - complications | Immunosuppressive Agents - adverse effects | Methotrexate - administration & dosage | Transaminases - blood | Aged | Atherosclerosis - prevention & control | Myocardial infarction | C-reactive protein | Heart attacks | Liver | Hematocrit | Cardiovascular disease | Angina | Metabolic syndrome | Folic acid | Interleukin 6 | Proteins | Atherosclerosis | Methotrexate | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Cerebral infarction | Cytokines | Diabetes mellitus | Inflammation | IL-1β | Patients | Investigations | Disease prevention | Rheumatoid arthritis | Arteriosclerosis | Monoclonal antibodies | Diabetes | Health risk assessment | Metabolic disorders | Pharmaceuticals
Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 01/2012, Volume 1247, Issue 1, pp. 83 - 96
Exposure to commensal and pathogenic organisms strongly influences our immune system. Exposure to helminths was frequent before humans constructed their...
macrophage | IBD | dendritic cells | autoimmunity | helminths | Treg | Autoimmunity | Dendritic cells | Helminths | Macrophage | COLLAGEN-INDUCED ARTHRITIS | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | HELIGMOSOMOIDES-POLYGYRUS INFECTION | TGF-BETA | MULTIDISCIPLINARY SCIENCES | T-reg | ALTERNATIVELY ACTIVATED MACROPHAGES | INFLAMMATORY-BOWEL-DISEASE | MULTIPLE-SCLEROSIS | REGULATORY T-CELLS | TRICHURIS-SUIS THERAPY | CHEMICALLY-INDUCED COLITIS | Inflammatory Bowel Diseases - prevention & control | Humans | Inflammatory Bowel Diseases - immunology | Immune System Diseases - immunology | Immune System Diseases - parasitology | Host-Parasite Interactions - immunology | Interferon-gamma - metabolism | Multiple Sclerosis - parasitology | Multiple Sclerosis - prevention & control | Immune System Diseases - prevention & control | Helminths - immunology | Inflammatory Bowel Diseases - parasitology | Animals | Interleukin-7 - immunology | Helminths - pathogenicity | Interferon-gamma - immunology | Multiple Sclerosis - immunology | Interleukin-7 - metabolism | Prevention | Multiple sclerosis | Parasitic diseases | Analysis | Transforming growth factors | T cells | Macrophages | Medical research | Bowel disease | Immune system
macrophage | IBD | dendritic cells | autoimmunity | helminths | Treg | Autoimmunity | Dendritic cells | Helminths | Macrophage | COLLAGEN-INDUCED ARTHRITIS | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | HELIGMOSOMOIDES-POLYGYRUS INFECTION | TGF-BETA | MULTIDISCIPLINARY SCIENCES | T-reg | ALTERNATIVELY ACTIVATED MACROPHAGES | INFLAMMATORY-BOWEL-DISEASE | MULTIPLE-SCLEROSIS | REGULATORY T-CELLS | TRICHURIS-SUIS THERAPY | CHEMICALLY-INDUCED COLITIS | Inflammatory Bowel Diseases - prevention & control | Humans | Inflammatory Bowel Diseases - immunology | Immune System Diseases - immunology | Immune System Diseases - parasitology | Host-Parasite Interactions - immunology | Interferon-gamma - metabolism | Multiple Sclerosis - parasitology | Multiple Sclerosis - prevention & control | Immune System Diseases - prevention & control | Helminths - immunology | Inflammatory Bowel Diseases - parasitology | Animals | Interleukin-7 - immunology | Helminths - pathogenicity | Interferon-gamma - immunology | Multiple Sclerosis - immunology | Interleukin-7 - metabolism | Prevention | Multiple sclerosis | Parasitic diseases | Analysis | Transforming growth factors | T cells | Macrophages | Medical research | Bowel disease | Immune system
Journal Article
The Lancet, ISSN 0140-6736, 03/2012, Volume 379, Issue 9822, pp. 1214 - 1224
Summary Background A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6...
Internal Medicine | C-REACTIVE PROTEIN | RHEUMATOID-ARTHRITIS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | SOLUBLE IL-6 | INDIVIDUAL PARTICIPANTS DATA | JOINT ANALYSIS | IL-6 RECEPTOR | GENOME-WIDE ASSOCIATION | TOCILIZUMAB | MEDICINE, GENERAL & INTERNAL | MECHANISMS | Antibodies, Monoclonal, Humanized - adverse effects | Gene Frequency - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Receptors, Interleukin-6 - genetics | Humans | Inflammation Mediators - blood | Genotype | Treatment Outcome | Receptors, Interleukin-6 - antagonists & inhibitors | Signal Transduction - genetics | Randomized Controlled Trials as Topic | Coronary Disease - prevention & control | Phenotype | Coronary Disease - genetics | Signal Transduction - drug effects | Mendelian Randomization Analysis | Polymorphism, Single Nucleotide - genetics | Genetic Variation - genetics | Prevention | Drug therapy | Coronary heart disease | Health aspects | Risk factors | Interleukin-6 | Cytokine receptors | Physiological aspects | Genetic aspects | Research | Studies | Medical research | Cardiovascular disease | Cholesterol | Cancer
Internal Medicine | C-REACTIVE PROTEIN | RHEUMATOID-ARTHRITIS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | SOLUBLE IL-6 | INDIVIDUAL PARTICIPANTS DATA | JOINT ANALYSIS | IL-6 RECEPTOR | GENOME-WIDE ASSOCIATION | TOCILIZUMAB | MEDICINE, GENERAL & INTERNAL | MECHANISMS | Antibodies, Monoclonal, Humanized - adverse effects | Gene Frequency - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Receptors, Interleukin-6 - genetics | Humans | Inflammation Mediators - blood | Genotype | Treatment Outcome | Receptors, Interleukin-6 - antagonists & inhibitors | Signal Transduction - genetics | Randomized Controlled Trials as Topic | Coronary Disease - prevention & control | Phenotype | Coronary Disease - genetics | Signal Transduction - drug effects | Mendelian Randomization Analysis | Polymorphism, Single Nucleotide - genetics | Genetic Variation - genetics | Prevention | Drug therapy | Coronary heart disease | Health aspects | Risk factors | Interleukin-6 | Cytokine receptors | Physiological aspects | Genetic aspects | Research | Studies | Medical research | Cardiovascular disease | Cholesterol | Cancer
Journal Article